# RMD — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-06-14. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 7.2 · Fundamentals 8.5 · Technicals 6 · Growth 6.5 · Risk 5.5

## Summary

ResMed offers a high-quality medical device franchise trading at a meaningful discount to its own history after a ~23% YoY decline driven by GLP-1 disruption fears, with shares near 52-week lows ($194.78 vs. $293.81 high) and forward P/E of ~16x against ~12% EPS growth and 25% ROE. Fundamentals remain robust (62% gross margin, 35% operating margin, $1.45B FCF, near-net-cash balance sheet), and the Kronos forecast plus a bullish sell-side target ($280.18) suggest a constructive near-to-mid-term setup, though the long-term GLP-1 secular question is unresolved.

## Price targets (12-month horizon)

- Bear: $165.00
- Base: $235.00
- Bull: $280.00

## News context

Newsflow is incrementally constructive but does not resolve the central debate. Two bullish-leaning items from 6/11 (Insider Monkey/Yahoo write-ups citing a Reddit bull thesis at $196.94, and Seeking Alpha's 'GLP-1 Threats Are Overstated' piece) directly push back on the dominant bear narrative, arguing share loss will be partial and remaining patients more profitable. The 6/5 Noctrix Health acquisition is a small but strategically interesting expansion into Restless Legs Syndrome via non-pharmacologic wearables — a credible adjacency that diversifies away from pure sleep apnea. Zacks/Yahoo (6/9) frame it as a 'retain' with acknowledged macro and competitive pressures. The William Blair conference appearance is a presence item, not a catalyst.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/rmd-ai-stock-forecast-e16ee4e83aadd67ca1662a0a2db21eac
- AI-generated; model outputs can be wrong. Not financial advice.